Chondrosarcoma natural history

Revision as of 17:43, 24 January 2019 by Rohan Bhimani (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Chondrosarcoma Microchapters


Patient Information


Historical Perspective




Differentiating Chondrosarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings


X Ray

Echocardiography and Ultrasound



Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chondrosarcoma natural history On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Chondrosarcoma natural history

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chondrosarcoma natural history

CDC on Chondrosarcoma natural history

Chondrosarcoma natural history in the news

Blogs on Chondrosarcoma natural history

Directions to Hospitals Treating Chondrosarcoma

Risk calculators and risk factors for Chondrosarcoma natural history

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rohan A. Bhimani, M.B.B.S., D.N.B., M.Ch.[2]


Complications that can develop as a result of chondrosarcoma are metastasis and recurrence. The prognosis of chondrosarcoma correlates with the grade and stage of the lesion at the time of diagnosis. Chondrosarcoma is associated with a 5 year survival rate of 70%. The presence of grade 3 lesions are associated with a particularly poor prognosis.

Natural History, Complications, and Prognosis



  • The prognosis of chondrosarcoma correlates with the grade and stage of the lesion at the time of diagnosis.[2]
    • Prognosis varies with grade:[3]
    • Grade I tumors - 90% survival at 5 years
    • Grade II tumors - 81% survival at 5 years
    • Grade III tumors - 29% survival at 5 years
  • Depending upon the subtype, prognosis vary substantially:[4]
    • Clear cell chondrosarcoma: 70% survival rate at 5 years.
    • Myxoid chondrosarcoma: 70% survival rate at 5 years.
    • Mesenchymal chondrosarcoma: < 50% survival rate at 5 years.
    • Dedifferentiated chondrosarcoma: 10% survival rate after 1 year.
  • Prognosis varies with location:[5]


  1. 1.0 1.1 Lalam RK, Cassar-Pullicino VN, Kumar N, Cool WP, Cribb GL, Mangham DC (2015). "Subcutaneous and lung metastases from chondrosarcoma of the thumb". BJR Case Rep. 1 (3): 20150129. doi:10.1259/bjrcr.20150129. PMC 6180831. PMID 30363596.
  2. Larramendy ML, Mandahl N, Mertens F, Blomqvist C, Kivioja AH, Karaharju E; et al. (1999). "Clinical significance of genetic imbalances revealed by comparative genomic hybridization in chondrosarcomas". Hum Pathol. 30 (10): 1247–53. PMID 10534175.
  3. Evans HL, Ayala AG, Romsdahl MM (1977). "Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading". Cancer. 40 (2): 818–31. PMID 890662.
  4. Dorfman HD, Czerniak B. Bone Tumors. St Louis: Mosby; 1998. 353-440.
  5. Peabody, Terrance (2014). Orthopaedic oncology : primary and metastatic tumors of the skeletal system. Cham: Springer. ISBN 9783319073224.